A Phase I/IIa First-in-Human Study of (212Pb)VMT-Alpha-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Protocol No
VMT-ALPHA-NET-T101
Staff Member
Alexandria T Phan
Phase
I/II
Summary

This project is being done to see if a study drug not yet approved for market, named of [212Pb]VMT- ALPHA-NET will help in the treatment of advanced tumors and how safe it is to use in people.

Objective
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Study Sites
Froedtert Hospital
Status
SUSPENDED